- Hoth Therapeutics Inc HOTH announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer’s disease mouse model.
- The data support the therapeutic cognitive potential of HT-ALZ after chronic oral dosing of 20mg/kg and 40mg/kg of HT-ALZ.
- HT-ALZ is therapeutic in development under the 505(b)(2) regulatory pathway for dementia related to Alzheimer’s.
- Hoth reports that the longer treatment before the beginning of testing improves the performance of more mice in the water maze and appears to affect anxiety-like behavior in the elevated plus maze positively.
- The groups of mice treated with the higher doses, 20mg/kg and 40mg/kg of HT-ALZ, appear to have the most benefit, with the 20mg group already showing significant improvement in spatial memory in the water maze.
- The elevated plus maze test is one of the most widely used tests for measuring anxiety-like behavior.
- Previously Hoth reported study results focused on investigating the effect of orally administered HT-ALZ to reduce the concentration of Aβ in the brain interstitial fluid.
- The initial data showed a significant decrease in Aβ in male and female mice after acute treatment with HT-ALZ, compared to placebo-treated animals and baseline Aβ levels.
- HOTH stock was up by 16% at one point during the premarket session.
- Price Action: HOTH shares are down 6.28% at $4.03 on the last check Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
